[Therapy of chronic ischemic heart disease and arterial hypertension by means of beta-receptor blockaders].
50 patients with stenocardias in persisting arterial hypertension, of them 33 manifest coronary diseases, were orally treated with doses of propranolol up to 400 mg/die during a longer period. In the majority of the cases a good to very good therapeutic effectivity was to be proved in hypertension as well as in chronic ischaemic heart disease. The own favourable results of the treatment justify the estimation that proporanolol may be regarded as therapeutic remedy of choice in patients with simultaneous hypertension and chronic ischaemic heart disease. Moreover, a collective of 45 patients with different cardiovascular diagnoses under the new selective beta-receptor blocker Bonnecor (practolol) was observed. It is reported on first experiences in the sense of an intermediate information.
D000328:Adult; D003327:Coronary Disease / Q000188:drug therapy*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use*
D011433:Propranolol; D011217:Practolol
Therapie der chronisch ischämischen Herzkrankheit und der arteriellen Hypertonie mit Beta-Rezeptorenblockern